Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 4/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18359585 | 0.85 | HTR2A (0.45) | GABRA5GABRA1HTR2AHTR2CALDH1A1 | |
| SCHEMBL18359624 | 0.83 | BRD4 (0.53) | ACSS2GABRA5GABRA1 | |
| SCHEMBL18326378 | 0.83 | GABRA5 (0.45) | GABRA5GABRA1HTR2AHTR2CALDH1A1 | |
| SCHEMBL29732326 | 0.83 | GABRA5 (0.45) | GABRA5GABRA1HTR2AHTR2CALDH1A1 | |
| SCHEMBL18359489 | 0.83 | KDM4E (0.43) | GABRA5GABRA1HTR2AHTR2CALDH1A1 | |
| SCHEMBL18359488 | 0.80 | PDE1A (0.45) | GABRA5GABRA1HTR2AHTR2CALDH1A1 | |
| SCHEMBL16896890 | 0.80 | HTR2A (0.43) | GABRA5GABRA1HTR2AHTR2CALDH1A1 | |
| SCHEMBL16896825 | 0.78 | HTR2A (0.44) | GABRA5GABRA1HTR2AHTR2CALDH1A1 | |
| SCHEMBL18326380 | 0.76 | PDE4D (0.42) | GABRA5GABRA1HTR2AHTR2CALDH1A1 | |
| SCHEMBL18326382 | 0.72 | HTR2A (0.43) | GABRA5GABRA1HTR2AHTR2CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-11-01 | — | — | US | disclosed |
| WO-2017001733-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD4, BRD2 | ACSS2 1822/4885GABRA5 3417/4885GABRA1 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.